The
global Biomarkers Market size is expected to reach USD
181.03 billion by 2030, registering a CAGR of 13.3% over the forecast period,
according to a new report by Grand View Research, Inc. The rising R&D
investments by pharmaceutical and biotechnology companies, increasing number of
Contract Research Organizations(CROs), and declining cost of clinical trials in
emerging economies are the major driving factors for the industry. In addition,
key players leverage various strategies to increase their production
capabilities and promote the outreach of their product offerings. In June 2022,
Paige announced its collaboration with Janssen to evaluate the potential of an
(H&E)-based, (AI)-powered biomarker test, developed by Janssen, to screen
for actionable FGFR3 and FGFR2 genomic alterations in patients with bladder
cancer.
The
increasing prevalence of chronic diseases like cancer, diabetes, and
cardiovascular disorders is anticipated to fuel industry growth. According to
the American Cancer Society, in 2022, an estimated 1.9 million new cancer cases
were registered in the U.S., accounting for 609,360 deaths. Breast and lung
cancers were observed as the most common ones worldwide. In addition, according
to a report published in 2020 by the Institute for Health Metrics and
Evaluation, cardiovascular diseases cause about 18.9 million deaths annually.
Increasing research focused on the identification of new diagnostic biomarkers is
fueling the industry's growth. For instance, in February 2022, Japanese
scientists found two new diagnostic tissue biomarkers, PHGDH and TRIM29,
indicated for malignant pleural mesothelioma.
These
agents can be used to diagnose mesothelioma quickly and help doctors in
differentiating between mesothelioma and other cancers. Moreover, in January
2020, a nascent research study published in the Journal of Nuclear Medicine
discussed the potential of several breast cancer biomarkers. A notable and
easily identifiable imaging biomarker recognized in the study was 18F-FDG PET.
Moreover, the COVID-19 pandemic has encouraged the use of biomarkers for
facilitating the detection & treatment of the disease. For instance, in
March 2021, a new biomarker-based screening device, named Tiger Tech COVID Plus
Monitor, was approved by the U.S. FDA.
The
device can be used for the identification of biomarkers for COVID-19 and other
hypercoagulable & hyperinflammatory conditions in individuals aged 5 years
& above. Furthermore, various strategic initiatives undertaken by leading
participants are anticipated to cater to demand. For instance, in August 2022,
Roche received the U.S. FDA approval for VENTANA MMR RxDx Panel to detect pMMR
endometrial cancer patients and dMMR solid tumor patients eligible for
treatment with Merck’s immunotherapy Keytruda. This approval for the VENTANA
MMR RxDx Panel is a label expansion of the company’s recent on-market panel.
Also, in December 2021, Siemens Healthineers partnered with Freenome to identify
novel suitable markers for the detection of early breast cancer to expand its
existing imaging technologies.
Related Press
Release@ Biomarkers Market Report
Biomarkers Market Report Highlights
- The safety
segment held the largest share in 2022 owing to the increased adoption of
safety biomarkers in drug discovery and development
- The efficacy
segment will register the fastest growth rate from 2023 to 2030 due to a
rise in strategic collaborations for promoting research activities
- The drug
discovery & development segment accounted for the largest share in
2022 due to the extensive R&D efforts taken by leading participants,
and the rising adoption of biomarkers in drug discovery
- The cancer
disease segment dominated the industry in 2022. However, the neurological
diseases segment is anticipated to record the fastest CAGRover the forecast
years
- Asia Pacific
is expected to be the fastest-growing region over the forecast period due
to the rising investments by key players and increasing disease prevalence
in the region
Related Reports
Cardiac
Biomarkers Market
Biomarkers Market Segmentation
Grand
View Research has segmented the global biomarkers market based on type,
application, disease, and region:
Biomarkers Type Outlook (Revenue, USD Billion, 2018
- 2030)
- Safety
- Efficacy
- Validation
Biomarkers Application Outlook (Revenue, USD
Billion, 2018 - 2030)
- Diagnostics
- Drug
Discovery & Development
- Personalized
Medicine
- Others
Biomarkers Disease Outlook (Revenue, USD Billion,
2018 - 2030)
- Cancer
- Safety
- Efficacy
- Validation
- Cardiovascular
Diseases
- Safety
- Efficacy
- Validation
- Neurological
Diseases
- Safety
- Efficacy
- Validation
- Immunological
Diseases
- Safety
- Efficacy
- Validation
- Others
- Safety
- Efficacy
- Validation
Biomarkers Regional Outlook (Revenue, USD Billion,
2018 - 2030)
- North
America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Spain
- France
- Italy
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
- Latin
America
- Brazil
- Mexico
- Argentina
- Middle East
& Africa
- South
Africa
- Saudi
Arabia
- UAE
- Kuwait
About Us:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals,
materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-95196
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment